Author(s): Pfutzner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, et al.
Objective: The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial.
Research design and methods: One-hundred twenty-five nondiabetic patients with increased cardiovascular risk [78 females, 47 males, age (mean+/-STD:58.6+/-7.8years, BMI:30.8+/-4.2(kg/m2] were included after randomization to PIO+lacebo, SIMVA+placebo, or PIO+SIMVA treatment for 3 months. At baseline and endpoint, measurements of HbA1c, glucose, insulin, LDL cholesterol, adiponectin and visfatin were performed. Insulin resistance was assessed by means of the HOMAIR-score.
Results: Improvement in the HOMAIR-score was observed with PIO and the combination, but not with SIMVA alone, which was accompanied by an increase in adiponectin with PIO treatment groups, but a decrease with SIMVA alone (baseline/endpoint: PIO: 14.0+/-8.2 mg/l/ 27.6+/- 14.5 mg/l, p<0.05; PIO+SIMVA: 11.7+/-10.0 mg/l/26.7+/-15.7 mg/l, p<0.05; SIMVA: 15.5+/-12.7 mg/l/ 11.6+/-7.0 mg/l, p<0.05). No change could be observed in the visfatin concentrations (PIO: 47.6+/-14.5 ng/ml/48.0+/-11.6 ng/ml, PIO+SIMVA: 45.1+/-10.9 ng/ml/47.9+/-10.1 ng/ml, SIMVA: 49.2+/- 13.4 ng/ml/52.1+/-16.7 ng/ml, n. s. in all cases).
Conclusions: Insulin resistance and/or cardiovascular risk indicators were not associated with visfatin levels. Regulation of visfatin secretion occurs through biochemical pathways independent from those influenced by pioglitazone or simvastatin.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/17952841
Author(s): Arner P
Author(s): Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, et al.
Author(s): Fantuzzi G
Author(s): Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP
Author(s): Adeghate E
Author(s): Alberti KG, Zimmet PZ
Author(s): Laakso M, Pyorala K
Author(s): Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al.
Author(s): Kim MK, Lee JH, Kim H, Park SJ, Kim SH, et al.
Author(s): Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, et al.
Author(s): Sakamoto A, Ishizaka Y, Toda E, Nagai R, Koike K, et al.
Author(s): Guagnano MT, Romano M, Falco A, Nutini M, Marinopiccoli M, et al.
Author(s): Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, et al.
Author(s): Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al.
Author(s): Kim JH, Kim SH, Im JA, Lee DC
Author(s): Kaminska A, Kopczynska E, Bronisz A, Zmudzinska M, Bielinski M, et al.
Author(s): Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, et al.
Author(s): García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, et al.
Author(s): Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ
Author(s): Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, et al.
Author(s): Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S et al.
Author(s): López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, et al.
Author(s): Kershaw EE, Flier JS
Author(s): Sharma AM, Chetty VT
Author(s): Fasshauer M, Paschke R